|
1
|
Beiki O, Hall P, Ekbom A and Moradi T:
Breast cancer incidence and case fatality among 4.7 million women
in relation to social and ethnic background: A population-based
cohort study. Breast Cancer Res. 14:R52012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang YL, Qian XL and Fu L: Comparison of
HER2 status of breast cancer between Chinese women in China and
Chinese-American women in the US. Breast J. 23:764–765. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang J, Li Q, Xu B, Zhang T, Chen S and
Luo Y: Efficacy and safety of duloxetine in Chinese breast cancer
patients with paclitaxel-induced peripheral neuropathy. Chin J
Cancer Res. 29:411–418. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Peng R, Luo C, Guo Q, Cao J, Yang Q, Dong
K, Wang S, Wang K and Song C: Association analyses of genetic
variants in long non-coding RNA MALAT1 with breast cancer
susceptibility and mRNA expression of MALAT1 in Chinese Han
population. Gene. 642:241–248. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Abrahams HJ, Gielissen MF, Schmits IC,
Verhagen CA, Rovers MM and Knoop H: Risk factors, prevalence, and
course of severe fatigue after breast cancer treatment: A
meta-analysis involving 12 327 breast cancer survivors. Ann Oncol.
27:965–974. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rossing M, Østrup O, Majewski WW, Kinalis
S, Jensen MB, Knoop A, Kroman N, Talman ML, Hansen TVO, Ejlertsen B
and Nielsen FC: Molecular subtyping of breast cancer improves
identification of both high and low risk patients. Acta Oncol.
57:58–66. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stathopoulos GP, Malamos NA, Markopoulos
C, Polychronis A, Armakolas A, Rigatos S, Yannopoulou A, Kaparelou
M and Antoniou P: The role of Ki-67 in the proliferation and
prognosis of breast cancer molecular classification subtypes.
Anticancer Drugs. 25:950–957. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xue J, Tarnasky HA, Rancourt DE and van
Der Hoorn FA: Targeted disruption of the testicular SPAG5/deepest
protein does not affect spermatogenesis or fertility. Mol Cell
Biol. 22:1993–1997. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shao X, Xue J and van der Hoorn FA:
Testicular protein Spag5 has similarity to mitotic spindle protein
Deepest and binds outer dense fiber protein Odf1. Mol Reprod Dev.
59:410–416. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fitzgerald CJ, Oko RJ and van der Hoorn
FA: Rat Spag5 associates in somatic cells with endoplasmic
reticulum and microtubules but in spermatozoa with outer dense
fibers. Mol Reprod Dev. 73:92–100. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhong W, Zhou Y, Li J, Mysore R, Luo W, Li
S, Chang MS, Olkkonen VM and Yan D: OSBP-related protein 8 (ORP8)
interacts with Homo sapiens sperm associated antigen 5 (SPAG5) and
mediates oxysterol interference of HepG2 cell cycle. Exp Cell Res.
322:227–235. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kersten FF, van Wijk E, Hetterschijt L,
Bauβ K, Peters TA, Aslanyan MG, van der Zwaag B, Wolfrum U, Keunen
JE, Roepman R and Kremer H: The mitotic spindle protein
SPAG5/Astrin connects to the Usher protein network postmitotically.
Cilia. 1:22012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yuan LJ, Li JD, Zhang L, Wang JH, Wan T,
Zhou Y, Tu H, Yun JP, Luo RZ, Jia WH and Zheng M: SPAG5
upregulation predicts poor prognosis in cervical cancer patients
and alters sensitivity to taxol treatment via the mTOR signaling
pathway. Cell Death Dis. 6:e17842015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Abdel-Fatah TMA, Agarwal D, Liu DX,
Russell R, Rueda OM, Liu K, Xu B, Moseley PM, Green AR, Pockley AG,
et al: SPAG5 as a prognostic biomarker and chemotherapy sensitivity
predictor in breast cancer: A retrospective, integrated genomic,
transcriptomic, and protein analysis. Lancet Oncol. 17:1004–1018.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stovgaard ES, Nielsen D, Hogdall E and
Balslev E: Triple negative breast cancer-prognostic role of
immune-related factors: A systematic review. Acta Oncol. 57:74–82.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kierszenbaum AL: Spermatid manchette:
Plugging proteins to zero into the sperm tail. Mol Reprod Dev.
59:347–349. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Podo F, Buydens LM, Degani H, Hilhorst R,
Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J,
Monleon D, et al: Triple-negative breast cancer: Present challenges
and new perspectives. Mol Oncol. 4:209–229. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang H, Li S, Yang X, Qiao B, Zhang Z and
Xu Y: miR-539 inhibits prostate cancer progression by directly
targeting SPAG5. J Exp Clin Cancer Res. 35:602016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cornen S, Guille A, Adélaïde J,
Addou-Klouche L, Finetti P, Saade MR, Manai M, Carbuccia N,
Bekhouche I, Letessier A, et al: Candidate luminal B breast cancer
genes identified by genome, gene expression and DNA methylation
profiling. PLoS One. 9:e818432014. View Article : Google Scholar : PubMed/NCBI
|
